InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing and commercializing potential best-in-class and/or first-in-class drugs for the treatment of cancers and autoimmune diseases – two large therapeutic areas with significant market opportunity and synergies. Led by a well-known management team of seasoned industry executives, we have built a fully integrated biopharmaceutical platform with strong in-house R&D, clinical development, manufacturing and commercialization capabilities. Our vision is to become a global biopharmaceutical leader that develops and delivers innovative therapies for patients worldwide. ...  

Leveraging our management team’s global vision and local expertise, we have built a differentiated and balanced drug portfolio, and have launched our first product Orelabrutinib in the market in 2021. Our robust pipeline includes 1 commercial product with 2 approved indications and additional 6 registrational trials, 10 clinical stage assets, over 30 trials ongoing globally, and another 4 to 5 IND enabling stage candidates. Our current pipeline drugs cover a variety of novel and validated therapeutic targets and drug modalities including monoclonal antibodies, bispecific antibodies, and small molecules across oncology and autoimmune diseases. 

Our drug candidates target both novel and evidence-based biological pathways. Our discovery and development efforts are focused on drug candidates with evidence- based targets that have the potential to be best-in-class from a safety and efficacy perspective. We also devote significant efforts in identifying novel targets and developing therapies with global breakthrough potential.  

We are well underway of building a leading hema-oncology franchise with (i) the core self- developed Orelabrutinib as a backbone therapy, (ii) the only U.S. FDA approved anti-CD19 antibody Tafasitamab for r/r DLBCL, (iii) multiple pipeline drugs that cover almost all important hema-oncology targets such as CD20xCD3, BCL-2 and E-3 ligase, and (iv) a well-established and focused commercialization platform in China.  

For the autoimmune diseases, we partnered with the global neurology leader Biogen in MS. Recently, we completed SLE Phase II trial in China and are actively pursuing further development of Orelabrutinib in SLE. We are also exploring Orelabrutinib for the treatment of ITP and NMOSD in Phase II trials. With the addition of our two TYK2 inhibitors (ICP-332 and ICP-488), we are well-positioned to provide oral drug solutions for substantial unmet clinical needs in autoimmune diseases.  

In the solid tumor field, we believe our potential best-in-class molecules ICP-192 targeting FGFR and ICP-723 targeting pan-TRK will enable us to establish a solid presence, while our rapidly growing and maturing early stage pipeline including ICP-033, ICP-189, ICP-B05 ICP-915 and ICP-B03 targeting novel targets such as SHP2 and CCR8 should enable us to provide a competitive treatment solution for a large array of solid tumors for both China and global patients in the future.  

With a proven excellency in small molecule R&D, we are establishing our internal biological drug R&D capability through internal and external efforts. We are also actively considering other new drug modalities such as PROTAC, ADC, molecule glue, and etc.  

With two significant business development deals struck in 2021, our business development team is well positioned to continue maximizing the value of our internal pipeline and strengthening our platform through in-licensing and out-licensing deals.